secwatch.observer — SEC 8-K summary
======================================

Issuer:     VYNE Therapeutics Inc. (VYNE)
CIK:        0001566044
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0001104659-23-116712
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VYNE raises $88.2M, reports positive Phase 1b vitiligo data for VYN201
----------------------------------------------------------------------

- $88.2M private placement closed Nov 1; cash runway extended through end of 2025.
- Phase 1b: VYN201 mean F-VASI reduction 30.2% (1%) and 39.0% (2%) at 16 weeks; well-tolerated.
- Phase 2b trial for VYN201 in vitiligo expected H1 2024; top-line results mid-2025.
- VYN202 IND submission by year-end 2023; Phase 1a trial in Q1 2024; Phase 1b in psoriasis/RA H2 2024.
- Q3 2023 GAAP net loss $6.6M, adjusted net loss $5.7M; cash runway through 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1566044/000110465923116712/0001104659-23-116712-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1566044/000110465923116712/tm2330394d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-116712

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer